Compare Becton Dickinson and Co (BDX) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Toronto-Dominion Bank — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Toronto-Dominion Bank trades at $123.47 (market cap $198.63B). The key difference: Toronto-Dominion Bank is far larger — about 4.8× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | TD | |
|---|---|---|
Market Cap | $41.51B | $198.63B |
Sector | Health | Financials |
52-Week High | $185.39 | $122.88 |
52-Week Low | $135.49 | $72.55 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
TD trades at $120.63, up 0.08% today, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 results pending. Revenue grew to $61.28 billion in 2025, and net income margin improved to 33.51%. Recent news highlights strong Q2 2026 earnings and a dividend increase.
The outlook is positive, supported by earnings momentum, a high analyst buy rating (52.94%), and operational efficiency gains from AI. Key risks include volatile cash flows, high debt levels, and economic sensitivity. The stock offers a solid dividend and growth potential, but investors should monitor credit performance and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
